New Psoriasis Medications: 8 Drugs Seeking FDA Approval

Your skin contributes to your appearance — color, wrinkles, freckles, and all. But it also supports your health. It protects you from germs and keeps your body at a stable temperature. That’s why protecting your skin is so important.

Yet, even with the best skin care routine, it’s hard to have perfect skin. Many things are out of your control. Inflammatory health conditions, such as psoriasis, can arise and disrupt your life. It can take many trips to the dermatologist and trying various moisturizers and medications before finding a treatment plan that works for you.

And that’s because there are quite a few options to choose from. Researchers have been developing and improving psoriasis medications for decades. The FDA has approved dozens of new psoriasis medications since the turn of the century alone — with a big focus on biologic medications. Health experts are expecting to see even more approved in the coming months and years.

1. Picankibart

Picankibart (IBI112) is a monoclonal antibody in development for plaque psoriasis. This under-the-skin injection interferes with an inflammatory protein called interleukin-23 (IL-23). This is comparable to psoriasis medications like Skyrizi (risankizumab) and Tremfya (guselkumab).

Blocking IL-23 appears to be an effective treatment strategy for many people. Up to 86% of people receiving the medication in a phase 2 study achieved at least 90% symptom improvement after 1 year of treatment. More recent phase 3 study data also demonstrated positive results.

Picankibart is approved in China under the brand name Pecondle. An FDA approval application may come next.

2. Ebdarokimab

Ebdarokimab (AK 101) is a monoclonal antibody medication that treats plaque psoriasis by targeting two inflammatory proteins, interleukin 12 (IL-12) and IL-23. This is similar to how Stelara (ustekinumab) works. It's given as a once-monthly, under-the-skin injection.

A phase 3 study found that people who received ebdarokimab for psoriasis saw significant improvement in their skin symptoms. After 1 year, around 80% of people who received the medication achieved at least a 75% reduction in psoriasis severity.

This treatment is now in advanced stages of development. It already finished two phase 3 studies in China, and it won Chinese approval in April 2025. It’s not fully clear if or when its manufacturer intend to apply for FDA approval.

3. Imsidolimab

Imsidolimab (ANB019) aims to treat a different form of psoriasis: generalized pustular psoriasis (GPP). People with GPP develop pus-filled bumps on different parts of their body. Imsidolimab works by blocking the interleukin-36 (IL-36) receptor, a protein that causes inflammation in GPP.

People with GPP can experience sudden and dangerous skin flare-ups. Phase 2 study results published in July 2023 found that this intravenous (IV) medication may provide quick and lasting relief. Some people experienced an improvement in their symptoms in as little as 3 days. These positive effects lasted for up to 3 months at a time.

A phase 3 study found that over half of people who received a single IV dose achieved clear or almost clear skin after 4 weeks (compared to 13% who received a placebo). In a follow-up study, 100% of people who continued monthly treatment maintained clear skin.

Imsidolimab’s application for FDA approval was accepted in February 2026. A decision on the application will likely come by December 2026. If it’s approved, imsidolimab would be the second FDA-approved medication for GPP. The first one was Spevigo (spesolimab).

4. Vunakizumab

Vunakizumab (SHR-1314) is an under-the-skin, monoclonal antibody injection that blocks the inflammatory protein interleukin-17 (IL-17). 

Its psoriasis study results have been positive, too. Phase 3 data published in January 2025 suggests that vunakizumab is safe and effective for treating moderate-to-severe plaque psoriasis. After 12 weeks (3 months) of treatment, over 70% of people experienced significant skin improvement. These benefits were generally maintained through 1 year of treatment. 

Vunakizumab was approved in China in August 2024. Its manufacturer has not submitted a U.S. approval application to the FDA.

5 Piclidenoson

Piclidenoson (CF101) is a twice-daily tablet in the works for plaque psoriasis. It’s a type of A3 adenosine receptor (A3AR) agonist. Piclidenoson attaches to A3AR, which is a protein that’s often found on unwanted inflammatory cells in the skin. It destroys the cells after it attaches. No psoriasis medications that are currently approved work this way.

So far, phase 3 study data found that piclidenoson was significantly better than placebo at helping people achieve 75% symptom improvement within 4 months of treatment.

Another phase 3 study is now on deck for piclidenoson. It began in mid 2025, and it should run until 2028. The company that makes piclidenoson is expected to submit an FDA-approval application as its phase 3 trial program matures.

6. Envudeucitinib

Envudeucitinib (ESK-001) is an oral medication being developed for moderate-to-severe plaque psoriasis. It belongs to a class of medications called TYK2 inhibitors, which work by blocking a specific pathway involved in immune system inflammation. This is similar to how Sotyktu (deucravacitinib) works, but envudeucitinib is designed to be more selective — potentially improving its effectiveness and safety profile.

Study results are promising so far. In a phase 2 study, people who took envudeucitinib daily experienced significant skin improvement.

More recent phase 3 data found that about two-thirds of people taking the medication saw their skin improve by at least 90% after about 6 months. And 4 in 10 had completely clear skin. Studies are ongoing.

7. ICP-488

ICP-488 is another TYK2 inhibitor in development for plaque psoriasis. It works by targeting the TYK2 protein, similar in style to Sotyktu and ESK-001.

So far, phase 2 trials suggest that ICP-488 significantly reduces psoriasis symptoms in people with moderate-to-severe symptoms. Over three-fourths of participants who received the medication achieved at least 75% symptom improvement within 12 weeks of starting the medication.

A phase 3 trial kicked off in March 2025 to confirm these findings. If ICP-488 continues to show strong results, it could become another oral alternative to biologics for psoriasis.

8. Biosimilars to current psoriasis treatments

A biosimilar is a “highly similar” version of another biologic. It’s meant to be a more affordable, yet equally-beneficial, alternative. It’s like a generic version of a brand-name drug.

Several biosimilars are available for use in the U.S., including some for plaque psoriasis. For instance, you may receive a Humira (adalimumab) biosimilar or a Remicade (infliximab) biosimilar instead of the original product — depending on your health insurance and infusion center. Several Stelara biosimilars have also been approved over the past year or so.

Even more biosimilars for psoriasis are slated to become available in the coming years. Keep an eye out for products such as BAT2306, which is a proposed Cosentyx (secukinumab) biosimilar.

Which medications are already approved to treat psoriasis?

No matter what type of psoriasis you have, how severe it is, or what your treatment goals are, you have several psoriasis treatment options to pick from.

Biologics

Biologic injections manage psoriasis symptoms by targeting specific parts of your immune system. You may receive a biologic by itself or in combination with other psoriasis treatments. Some are infused into a vein, while others are injected under your skin:

• Humira

• Cimzia (certolizumab pegol)

• Enbrel (etanercept)

• Remicade

• Cosentyx

• Bimzelx (bimekizumab)

• Siliq (brodalumab)

• Taltz (ixekizumab)

• Ilumya (tildrakizumab)

• Skyrizi 

• Tremfya

• Stelara (ustekinumab)

• Spevigo

The bottom line

Many new psoriasis medications are in development. If approved, piclidenoson tablets would be the first medication of its kind. Imsidolimab infusions could offer fast-acting relief for a form of psoriasis that causes pus-filled bumps. And several new biosimilars may help with out-of-pocket savings. Check back with GoodRx for updates on the latest psoriasis medication approvals.

Why trust our experts?

Written by:

Joshua Murdock, PharmD, BCBBS

Joshua Murdock, PharmD, BCBBS, is a licensed pharmacist in Arizona, Colorado, and Rhode Island. He has worked in the pharmacy industry for more than 10 years and currently serves as a pharmacy editor for GoodRx.

Reviewed by:

Maria Robinson, MD, MBA

Maria Robinson, MD, MBA, is a board-certified dermatologist and dermatopathologist who has practiced dermatology and dermatopathology for over 10 years across private practice, academic, and telehealth settings. She is a fellow of the American Academy of Dermatology and the American Society of Dermatopathology.

Our editorial standards

Meet our experts

References

Alumis. (2024). Alumis initiates ONWARD Phase 3 clinical program evaluating ESK-001, an oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. 

Alumis. (2025). Alumis completes enrollment of pivotal phase 3 ONWARD clinical program of lead candidate ESK-001, a highly selective, next-generation oral TYK2 inhibitor for the treatment of moderate-to-severe plaque psoriasis.

View All References (33)

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Alumis. (2024). Alumis initiates ONWARD Phase 3 clinical program evaluating ESK-001, an oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. 

Alumis. (2025). Alumis completes enrollment of pivotal phase 3 ONWARD clinical program of lead candidate ESK-001, a highly selective, next-generation oral TYK2 inhibitor for the treatment of moderate-to-severe plaque psoriasis.

American Academy of Dermatology Association. (n.d.). Psoriasis clinical guideline. 

AnaptysBio. (2023). Anaptys announces positive top-line Phase 3 clinical trial results of imsidolimab (IL-36R) in generalized pustular psoriasis (GPP). 

Bio-Thera Solutions. (2024). Bio-Thera Solutions and Pharmapark further expand partnership in Russia and other CIS countries with addition of BAT2306, a Cosentyx biosimilar.

Brownstone, N. D., et al. (2020). Biologic treatments of psoriasis: An update for the clinician. Biologics: Targets and Therapy. 

Can-Fite BioPharma. (2022). Can-Fite announces positive top-line results from piclidenoson Phase III COMFORT study in moderate to severe psoriasis. Business Wire.

Can-Fite BioPharma. (2023). Can-Fite receives U.S. FDA’s go ahead for piclidenoson psoriasis registration plan. Business Wire.

ClinicalTrials.gov. (2023). A Phase 3 study of efficacy and safety of AK101 in subjects with psoriasis. National Library of Medicine.

ClinicalTrials.gov. (2024). A Phase 3 study in moderate-to-severe plaque psoriasis with piclidenoson to study safety and efficacy. National Library of Medicine.

ClinicalTrials.gov. (2024). A study to evaluate IBI112 in the treatment of psoriasis with moderate to severe plaque psoriasis. National Library of Medicine. 

ClinicalTrials.gov. (2025). Efficacy, safety, pharmacokinetics of ICP-488 in patients with moderate to severe plaque psoriasis. National Library of Medicine.

Crescioli, S., et al. (2024). Antibodies to watch in 2025. mAbs. 

Fidler, B. (2024). Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu. BioPharma Dive.

Fishman, P. (2022). Drugs targeting the A3 adenosine receptor: Human clinical study data. Molecules. 

Ghosh, S. (2024). Psoriasis biosimilars market is forecasted to reach an impressive USD 26,679.9 million by 2034, reflecting a robust CAGR of 11.2%. Future Market Insights. 

Grasso, G. M., et al. (2025). ‘Strong data’ support ESK-001’s potential as oral treatment for plaque psoriasis. Healio.

InnoCare. (2024). InnoCare announces Phase II study results of TYK2 inhibitor ICP-488 meet primary endpoint in psoriasis patients. 

Innovent Biologics. (2023). Innovent announces first patient dosed in a Phase 3 clinical trial (CLEAR) of picankibart (anti-IL23p19 monoclonal antibody) in patients with moderate-to-severe plaque psoriasis. PR Newswire. 

Innovent Biologics. (2025). China's first domestic IL-23p19 monoclonal antibody: Innovent's PECONDLE (picankibart injection) received NMPA approval.

Johnson & Johnson. (2024). Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results. 

Johnson & Johnson. (2025). Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis.

Keam, S. J. (2024). Vunakizumab: First approval. Drugs. 

Lopez-Ojeda, W., et al. (2022). Anatomy, skin (integument). StatPearls.

Ludmann, P. (2024). Pustular psoriasis: Treatment. American Academy of Dermatology Association.

National Psoriasis Foundation. (n.d.). Current biologics on the market. 

National Psoriasis Foundation. (2019). Two centuries of progress in one short timeline. 

National Psoriasis Foundation. (2023). Oral treatments.

National Psoriasis Foundation. (2023). Over-the-counter topicals. 

Sami, T. (2025). Akeso scores China approval for ebdarokimab in plaque psoriasis. BioWorld.

Taylor, P. (2026). Alumis shoots up as its Sotyktu rival aces psoriasis trials. PharmaPhorum.

Vanda Pharmaceuticals. (2026). Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for imsidolimab for the treatment of generalized pustular psoriasis.

Waldron, J. (2024). Innovent, awaiting Chinese regulators' verdict, posts another psoriasis win for IL-23 drug. Fierce Biotech.

Warren, R. B., et al. (2023). Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: Results from the phase II GALLOP trial. British Journal of Dermatology.

Yan, K., et al. (2024). Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology.